Case Presentation: We present a case of a 65 year old female with a recent diagnosis of small cell lung cancer (SCLC) who had completed four cycles of carboplatin and etoposide. She was subsequently initiated on maintenance program cell death ligands (PD-L1) inhibitor, atezolizumab every three weeks since January 2019. Seven months after initiation, she […]